STAMPEDE: Front-Line Docetaxel Prolongs Survival in Metastatic Prostate Cancer

In this video, Dr. Nicholas David James discusses the results of the STAMPEDE trial, which tested front-line docetaxel combined with hormonal therapy in patients with advanced, hormone-naive prostate cancer.

Related Content:

American Society of Clinical Oncology Annual Meeting (ASCO)Prostate Cancer

Genomic Test Does Not Increase Active Surveillance Acceptance for Treating Favorable-Risk Prostate Cancer

Prostate Cancer Focal Therapy Has Made Great Strides and the Future Remains Bright

Primary Focal Therapy for Localized Prostate Cancer: A Review of the Literature